Literature DB >> 17765612

Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia.

Rafael Rosso1, Jonathan M Kalman, Ori Rogowski, Shmuel Diamant, Amir Birger, Simon Biner, Bernard Belhassen, Sami Viskin.   

Abstract

BACKGROUND: The mainstay of therapy for catecholaminergic polymorphic ventricular tachycardia (CPVT) is maximal doses of beta-blockers. However, although beta-blockers prevent exercise-induced ventricular tachycardia (VT), most patients continue to have ventricular ectopy during exercise, and some studies report high mortality rates despite beta-blockade.
OBJECTIVE: The purpose of this study was to investigate whether combining a calcium channel blocker with beta-blockers would prevent ventricular arrhythmias during exercise better than beta-blockers alone since the mutations causing CPVT lead to intracellular calcium overload.
METHODS: Five patients with CPVT and one with polymorphic VT (PVT) and hypertrophic cardiomyopathy who had exercise-induced ventricular ectopy despite beta-blocker therapy were studied. Symptom-limited exercise was first performed during maximal beta-blocker therapy and repeated after addition of oral verapamil.
RESULTS: When comparing exercise during beta-blockers with exercise during beta-blockers + verapamil, exercise-induced arrhythmias were reduced: (1) Three patients had nonsustained VT on beta-blockers, and none of them had VT on combination therapy. (2) The number of ventricular ectopics during the whole exercise test went down from 78 +/- 59 beats to 6 +/- 8 beats; the ratio of ventricular ectopic to sinus beats during the 10-second period recorded at the time of the worst ventricular arrhythmia went down from 0.9 +/- 0.4 to 0.2 +/- 0.2. One patient with recurrent spontaneous VT leading to multiple shocks from her implanted cardioverter-defibrillator (ICD) despite maximal beta-blocker therapy (14 ICD shocks over 6 months while on beta-blockers) has remained free of arrhythmias (for 7 months) since the addition of verapamil therapy.
CONCLUSIONS: This preliminary evidence suggests that beta-blockers and calcium blockers could be better than beta-blockers alone for preventing exercise-induced arrhythmias in CPVT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17765612     DOI: 10.1016/j.hrthm.2007.05.017

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  35 in total

1.  Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Hyun Seok Hwang; Can Hasdemir; Derek Laver; Divya Mehra; Kutsal Turhan; Michela Faggioni; Huiyong Yin; Björn C Knollmann
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-01-26

2.  It is not always digitalis: bidirectional ventricular tachycardia in left ventricular hypertrophy.

Authors:  Hendrik Bonnemeier; Melanie Barantke
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-04       Impact factor: 1.468

3.  Power and pitfalls of using transgenic mice to optimize therapy for CPVT: a need for prospective placebo-controlled clinical trials in genetic arrhythmia disorders.

Authors:  Björn C Knollmann
Journal:  Heart Rhythm       Date:  2010-07-29       Impact factor: 6.343

4.  Clinical effectiveness of pulmonary vein isolation for arrhythmic events in a patient with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Naokata Sumitomo; Takahiro Nakamura; Junji Fukuhara; Toshiko Nakai; Ichiro Watanabe; Hideo Mugishima; Masayasu Hiraoka
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

Review 5.  Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia.

Authors:  Michela Faggioni; Dmytro O Kryshtal; Björn C Knollmann
Journal:  Pediatr Cardiol       Date:  2012-03-16       Impact factor: 1.655

6.  Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice.

Authors:  Guy Katz; Assad Khoury; Efrat Kurtzwald; Edith Hochhauser; Eyal Porat; Asher Shainberg; Jonathan G Seidman; Christine E Seidman; Abraham Lorber; Michael Eldar; Michael Arad
Journal:  Heart Rhythm       Date:  2010-07-08       Impact factor: 6.343

7.  Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Christian van der Werf; Prince J Kannankeril; Frederic Sacher; Andrew D Krahn; Sami Viskin; Antoine Leenhardt; Wataru Shimizu; Naokata Sumitomo; Frank A Fish; Zahurul A Bhuiyan; Albert R Willems; Maurits J van der Veen; Hiroshi Watanabe; Julien Laborderie; Michel Haïssaguerre; Björn C Knollmann; Arthur A M Wilde
Journal:  J Am Coll Cardiol       Date:  2011-05-31       Impact factor: 24.094

8.  Ventricular arrhythmia in children: diagnosis and management.

Authors:  Gerald Serwer
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-09

9.  Risk stratification in young patients with channelopathies.

Authors:  N Sreeram; U Trieschmann; M Khalil; M Emmel
Journal:  Indian Pacing Electrophysiol J       Date:  2010-06-05

10.  Impaired calcium-calmodulin-dependent inactivation of Cav1.2 contributes to loss of sarcoplasmic reticulum calcium release refractoriness in mice lacking calsequestrin 2.

Authors:  Dmytro O Kryshtal; Oleksiy Gryshchenko; Nieves Gomez-Hurtado; Bjorn C Knollmann
Journal:  J Mol Cell Cardiol       Date:  2015-03-07       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.